<p>Pulse Biosciences, Inc.（纳斯达克股票代码：PLSE - 获取免费报告）在六月份看到了空头头寸大幅下降。截至 6 月 15 日，空头头寸总计 2,430,000 股，较 5 月 31 日的 2,840,000 股减少了 14.4%。根据平均每日交易量为 220,500 股，目前的空头头寸比率为 11.0 天。目前，该公司的 14.9% 股份被空头持有。</p>
<p>获取 <strong>Pulse Biosciences</strong> 警报：</p>
<h2>Pulse Biosciences 股票表现</h2>
<p>纳斯达克 PLSE 股票周五开盘价为$11.19。Pulse Biosciences 过去 12 个月的最低价为$3.78，最高价为$14.96。该公司的 50 天简单移动平均价为$10.06，200 天简单移动平均价为$9.55。</p>
<p>Pulse Biosciences（纳斯达克股票代码：PLSE - 获取免费报告）最近公布了其截至 5 月 7 日星期二的季度财报数据。该公司报告该季度每股亏损为（$0.17）。</p>
<h2>华尔街分析师观点</h2>
<p>StockNews.com 在一份研究报告中将 Pulse Biosciences 股票评级升级为 “卖出”。</p>
<p><strong>阅读我们关于 Pulse Biosciences 的最新报告</strong></p>
<h2>内部人员的买卖行为</h2>
<p>据相关消息，首席执行官 Burke Thomas Barrett 于 5 月 20 日星期一购买了该公司 10,000 股股票。股票的平均购入成本为每股$8.56，总交易额为$85,600.00。购买后，首席执行官现在直接持有该公司 10,000 股股票，价值$85,600。该购买行为已在提交给证券交易委员会的文件中披露，可通过此超链接访问。公司股份的 71.50% 归内部人员所有。</p>
<h2>对 Pulse Biosciences 的对冲基金观点</h2>
<p>一些大型投资者最近调整了他们在 PLSE 的持仓。BNP Paribas Financial Markets 在第一季度将其在 Pulse Biosciences 的持股比例提高了 63.6%。BNP Paribas Financial Markets 现在拥有 7,597 股该公司股票，价值$66,000，比上期增加了 2,952 股。Price T Rowe Associates Inc. MD 在第一季度新买入了 Pulse Biosciences 的股票，价值$88,000。Cetera Advisors LLC 在第一季度新买入了 Pulse Biosciences 的股票，价值$109,000。PNC Financial Services Group Inc.在第四季度新买入了 Pulse Biosciences 的股票，价值$242,000。最后，Inspire Investing LLC 在第一季度将其在 Pulse Biosciences 的持股比例提高了 32.1%。Inspire Investing LLC 现在拥有 41,358 股该公司股票，价值$360,000，比上期增加了 10,039 股。目前，76.95% 的股份由机构投资者和对冲基金持有。</p>
<h2>关于 Pulse Biosciences（获取免费报告）</h2>
<p>Pulse Biosciences, Inc 是一家新型生物电医学公司。该公司提供 CellFX 系统，这是一个可调节、软件启用和基于控制台的平台，通过其 Nano-Pulse 刺激技术向非热清除靶向细胞传递纳秒持续时间的电能脉冲，同时保护相邻的非细胞组织，以治疗各种疾病。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票比 Pulse Biosciences 更好</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>Upwork 股票展望：尽管面临 Gen-AI 挑战，数字仍坚实</li>
<li>股市板块：它们是什么，有多少个？</li>
<li>瓦尔格林斯股票暴跌背后的原因：投资者下一步该怎么做</li>
<li>什么是华尔街赌注，他们瞄准哪些股票？</li>
<li>MarketBeat 周评-6/24 - 6/28</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ AI 真正的下一步发展方向（来自 InvestorPlace）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2"/></p>
<h2>您现在是否应该投资$1,000 购买 Pulse Biosciences 股票？</h2>
<p>在考虑 Pulse Biosciences 之前，您可能想听听这个。</p>
<p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Pulse Biosciences 不在名单上。</p>
<p>尽管 Pulse Biosciences 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PLSE

<p>Pulse Biosciences（纳斯达克股票代码：PLSE）在六月份经历了空头头寸的显著下降，与五月相比下降了 14.4%。目前，该公司的股份中有 14.9% 被空头卖空。根据平均每日交易量，按照股票的交易天数计算，空头头寸的天数为 11.0 天。过去一年，该公司的股价表现在 3.78 美元至 14.96 美元之间波动。首席执行官 Burke Thomas Barrett 最近购买了 10,000 股该公司的股票。机构投资者和对冲基金持有该股约 76.95%</p>

<p>Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 2,430,000 shares, a drop of 14.4% from the May 31st total of 2,840,000 shares. Based on an average daily volume of 220,500 shares, the short-interest ratio is currently 11.0 days. Currently, 14.9% of the shares of the company are sold short.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc.（纳斯达克股票代码：PLSE - 获取免费报告）在六月份看到了空头头寸大幅下降。截至 6 月 15 日，空头头寸总计 2,430,000 股，较 5 月 31 日的 2,840,000 股减少了 14.4%。根据平均每日交易量为 220,500 股，目前的空头头寸比率为 11.0 天。目前，该公司的 14.9% 股份被空头持有。</p>
</div><p>Get <strong>Pulse Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pulse Biosciences</strong> 警报：</p>
</div><h2>Pulse Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Pulse Biosciences 股票表现</h2>
</div><p>Shares of NASDAQ PLSE opened at $11.19 on Friday. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96. The company has a 50 day simple moving average of $10.06 and a two-hundred day simple moving average of $9.55.</p>
<div class="lb-trans"><p>纳斯达克 PLSE 股票周五开盘价为$11.19。Pulse Biosciences 过去 12 个月的最低价为$3.78，最高价为$14.96。该公司的 50 天简单移动平均价为$10.06，200 天简单移动平均价为$9.55。</p>
</div><p>Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.</p>
<div class="lb-trans"><p>Pulse Biosciences（纳斯达克股票代码：PLSE - 获取免费报告）最近公布了其截至 5 月 7 日星期二的季度财报数据。该公司报告该季度每股亏损为（$0.17）。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, StockNews.com upgraded shares of Pulse Biosciences to a &#34;sell&#34; rating in a research note on Thursday.</p>
<div class="lb-trans"><p>StockNews.com 在一份研究报告中将 Pulse Biosciences 股票评级升级为 “卖出”。</p>
</div><p><strong>Read Our Latest Report on Pulse Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Pulse Biosciences 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员的买卖行为</h2>
</div><p>In related news, CEO Burke Thomas Barrett bought 10,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was bought at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the purchase, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $85,600. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 71.50% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>据相关消息，首席执行官 Burke Thomas Barrett 于 5 月 20 日星期一购买了该公司 10,000 股股票。股票的平均购入成本为每股$8.56，总交易额为$85,600.00。购买后，首席执行官现在直接持有该公司 10,000 股股票，价值$85,600。该购买行为已在提交给证券交易委员会的文件中披露，可通过此超链接访问。公司股份的 71.50% 归内部人员所有。</p>
</div><h2>Hedge Funds Weigh In On Pulse Biosciences</h2>
<div class="lb-trans"><h2>对 Pulse Biosciences 的对冲基金观点</h2>
</div><p>Several large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock valued at $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $88,000. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $109,000. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $242,000. Finally, Inspire Investing LLC lifted its stake in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after purchasing an additional 10,039 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了他们在 PLSE 的持仓。BNP Paribas Financial Markets 在第一季度将其在 Pulse Biosciences 的持股比例提高了 63.6%。BNP Paribas Financial Markets 现在拥有 7,597 股该公司股票，价值$66,000，比上期增加了 2,952 股。Price T Rowe Associates Inc. MD 在第一季度新买入了 Pulse Biosciences 的股票，价值$88,000。Cetera Advisors LLC 在第一季度新买入了 Pulse Biosciences 的股票，价值$109,000。PNC Financial Services Group Inc.在第四季度新买入了 Pulse Biosciences 的股票，价值$242,000。最后，Inspire Investing LLC 在第一季度将其在 Pulse Biosciences 的持股比例提高了 32.1%。Inspire Investing LLC 现在拥有 41,358 股该公司股票，价值$360,000，比上期增加了 10,039 股。目前，76.95% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>About Pulse Biosciences (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Pulse Biosciences（获取免费报告）</h2>
</div><p>Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.</p>
<div class="lb-trans"><p>Pulse Biosciences, Inc 是一家新型生物电医学公司。该公司提供 CellFX 系统，这是一个可调节、软件启用和基于控制台的平台，通过其 Nano-Pulse 刺激技术向非热清除靶向细胞传递纳秒持续时间的电能脉冲，同时保护相邻的非细胞组织，以治疗各种疾病。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Pulse Biosciences</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票比 Pulse Biosciences 更好</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>Upwork 股票展望：尽管面临 Gen-AI 挑战，数字仍坚实</li>
<li>股市板块：它们是什么，有多少个？</li>
<li>瓦尔格林斯股票暴跌背后的原因：投资者下一步该怎么做</li>
<li>什么是华尔街赌注，他们瞄准哪些股票？</li>
<li>MarketBeat 周评-6/24 - 6/28</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前经 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Where AI is REALLY Going Next (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ AI 真正的下一步发展方向（来自 InvestorPlace）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8506&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pulse Biosciences right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 购买 Pulse Biosciences 股票？</h2>
</div><p>Before you consider Pulse Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Pulse Biosciences 之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Pulse Biosciences 不在名单上。</p>
</div><p>While Pulse Biosciences currently has a &#34;hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Pulse Biosciences 目前在分析师中有 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Pulse Biosciences, Inc. (NASDAQ:PLSE) 空头头寸最新动态